Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
PMC 7694556
This covalent modification disrupts the Keap1-Nrf2 complex, liberating Nrf2 to translocate to the nucleus
Kouichi Tamura has received honoraria/lecture fee from AstraZeneca, Novartes, Bayer, Otsuka Pharmaceutical, Boehringer Ingelheim, Fuji Pharma, Kyowa Kirin, Ono Pharmaceutical, Sanwa Kagaku, Mochida Pharmaceutical, Kowa, Eli Lilly, Novo Nordisk, commissioned clinical trials, contract research and joint research funding: AstraZeneca, Bayer, Novartis, Chinook, Otsuka Medical Devices, Novo Nordisk, Terumo, Variatris, and Kowa, and, Scholarship donations: Otsuka Pharmaceutical, Bayer, Mochida Pharmaceutical, and Boehringer Ingelheim
Contact us today to address your questions and help your patients begin their journey to improved health
)
